Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Between 2018 and 2024, China has launched 188 domestically developed innovative drugs – nearly double the number from the ...

Regeneron (NASDAQ: REGN) is testing its drug, trevogrumab, along with Wegovy and another treatment, garetosmab, in a ...

These three stocks just announced significant quarterly dividend increases that they are set to pay out soon. While they all raised dividends by a minimum of 15%, two announced raises north of 35%.

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

Six percent of Americans have used Ozempic, Wegovy and similar drugs. They’re unwitting experimental subjects.

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...